Cortistatin inhibits growth hormone release from human fetal and adenoma pituitary cells and prolactin secretion from cultured prolactinomas

被引:22
作者
Rubinfeld, Hadara
Hadani, Moshe
Barkai, Gad
Taylor, John E.
Culler, Michael D.
Shimon, Ilan
机构
[1] Rabin Med Ctr, Inst Endocrinol & Metab, IL-49100 Petah Tiqwa, Israel
[2] Rabin Med Ctr, Felsenstein Med Res Ctr, IL-49100 Petah Tiqwa, Israel
[3] Chaim Sheba Med Ctr, Dept Neurosurg, IL-52621 Tel Hashomer, Israel
[4] Chaim Sheba Med Ctr, Dept Human Genet, IL-52621 Tel Hashomer, Israel
[5] Tel Aviv Univ, Sackler Sch Med, IL-69978 Tel Aviv, Israel
[6] IPSEN Grp, Milford, MA 01757 USA
关键词
D O I
10.1210/jc.2005-2148
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context: Cortistatin (CST) is a neuropeptide that shares high homology with somatostatin and binds with high affinity to all somatostatin receptor (SSTR) subtypes. Many of its endocrine and biological activities overlap with those of somatostatin. Objective/Design: The objective of the study was to assess the direct in vitro effects of CST on human pituitary hormone secretion. Setting: This study was performed in the endocrine laboratory of a tertiary academic medical center. Materials: Primary cell cultures of human fetal (21-25 wk gestation) pituitary tissues and cultured hormone-secreting adenoma cells were used in this study. Interventions: Cell cultures were incubated with CST-14 or CST-17, somatostatin, GHRH, SSTR analogs, and ghrelin analogs, and hormone secretion was analyzed. Outcome Measures: GH and prolactin (PRL) medium concentrations were tested by hormone assay, and SSTR mRNA was tested by RT-PCR. Results: CST-14 (10 nM) inhibited GH secretion by up to 65% in all fetal pituitary specimens after 4-h incubation (P < 0.05). CST-14 or CST-17 (10 nM) inhibited basal GH secretion in six of the 13 GH-cell adenomas and two of the three GH-PRL mixed adenomas. CST-17 (100 nM) suppressed the GH response to GHRH and ghrelin analog (10 nM each) by 30-50% in adenomas (P < 0.05). Three PRL-adenomas treated with CST-17 (10 nM) showed a 20-40% inhibition of PRL release (P < 0.05), whereas in three others no suppression or mild response was achieved at this concentration. A comparable inhibition of PRL secretion was obtained with SSTR5-selective analog but significantly less with SSTR2-preferential compounds. RT-PCR revealed the expression of both SSTR2 and SSTR5 in all GH-cell and mixed adenomas studied and all PRL-secreting adenomas studied, except for two of the CST-resistant prolactinomas, in which SSTR5 was absent. Conclusions: This is the first report of in vitro CST suppression of human GH and PRL in cultured pituitary tissues. The regulation of PRL release from cultured adenomas appears to be primarily mediated by SSTR5.
引用
收藏
页码:2257 / 2263
页数:7
相关论文
共 33 条
  • [1] Expression of cortistatin and MrgX2, a specific cortistatin receptor, in human neuroendocrine tissues and related tumours
    Allia, E
    Tarabra, E
    Volante, M
    Cerrato, M
    Ghigo, E
    Muccioli, G
    Papotti, M
    [J]. JOURNAL OF PATHOLOGY, 2005, 207 (03) : 336 - 345
  • [2] Growth hormone secretagogues and hypothalamic networks
    Bluet-Pajot, MT
    Tolle, V
    Zizzari, P
    Robert, C
    Hammond, C
    Mitchell, V
    Beauvillain, JC
    Viollet, C
    Epelbaum, J
    Kordon, C
    [J]. ENDOCRINE, 2001, 14 (01) : 1 - 8
  • [3] Endocrine activities of cortistatin-14 and its interaction with GHRH and ghrelin in humans
    Broglio, F
    Arvat, E
    Benso, A
    Gottero, C
    Prodam, F
    Grottoli, S
    Papotti, M
    Muccioli, G
    van der Lely, AJ
    Deghenghi, R
    Ghigo, E
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2002, 87 (08) : 3783 - 3790
  • [4] ABSENCE OF SUPPRESSIVE EFFECT OF SOMATOSTATIN ON PROLACTIN LEVELS IN PATIENTS WITH HYPERPROLACTINEMIA
    BRONSTEIN, MD
    KNOEPFELMACHER, M
    LIBERMAN, B
    MARINO, R
    GERMEK, OA
    SCHALLY, AV
    [J]. HORMONE AND METABOLIC RESEARCH, 1987, 19 (06) : 271 - 274
  • [5] Cortistatin-14 inhibits cell proliferation of human thyroid carcinoma cell lines of both follicular and parafollicular origin
    Cassoni, P
    Muccioli, G
    Marrocco, I
    Volante, M
    Allia, E
    Ghigo, E
    Deghenghi, R
    Papotti, M
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2002, 25 (04) : 362 - 368
  • [6] THE FUTURE OF THE FETAL TISSUE-BANK
    COHEN, CB
    JONSEN, AR
    [J]. SCIENCE, 1993, 262 (5140) : 1663 - 1665
  • [7] Cortistatin rather than somatostatin as a potential endogenous ligand for somatostatin receptors in the human immune system
    Dalm, VA
    van Hagen, PM
    van Koetsveld, PM
    Langerak, AW
    van der Lely, AJ
    Lamberts, SW
    Hofland, LJ
    [J]. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2003, 88 (01) : 270 - 276
  • [8] Distribution pattern of somatostatin and cortistatin mRNA in human central and peripheral tissues
    Dalm, VASH
    Van Hagen, PM
    de Krijger, RR
    Kros, JM
    Van Koetsveld, PM
    Van Der Lely, AJ
    Lamberts, SWJ
    Hofland, LJ
    [J]. CLINICAL ENDOCRINOLOGY, 2004, 60 (05) : 625 - 629
  • [9] Targeting the ghrelin receptor - Orally active GHS and cortistatin analogs
    Deghenghi, R
    Broglio, F
    Papotti, M
    Muccioli, G
    Ghigo, E
    [J]. ENDOCRINE, 2003, 22 (01) : 13 - 18
  • [10] Growth hormone-inhibiting activity of cortistatin in the rat
    Deghenghi, R
    Avallone, R
    Torsello, A
    Muccioli, G
    Ghigo, E
    Locatelli, V
    [J]. JOURNAL OF ENDOCRINOLOGICAL INVESTIGATION, 2001, 24 (11) : RC31 - RC33